Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.

Description

In an effort to elucidate whether the Harmonic Scalpel will improve sealing lymphatics and decrease lymphatic drainage thereby decreasing the length of time that chest tubes are required and minimizing length of stay; the Harmonic Scalpel will be compared to a control group which uses electrocautery. This study will assess these two different methods to determine if there is a notable decrease in the amount of drainage with one versus the other.

Conditions

Lung Cancer

Study Overview

Study Details

Study overview

In an effort to elucidate whether the Harmonic Scalpel will improve sealing lymphatics and decrease lymphatic drainage thereby decreasing the length of time that chest tubes are required and minimizing length of stay; the Harmonic Scalpel will be compared to a control group which uses electrocautery. This study will assess these two different methods to determine if there is a notable decrease in the amount of drainage with one versus the other.

Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy. A Single Center Prospective Randomized Controlled Study.

Use of Harmonic Scalpel to Decrease Lymphatic and Chest Tube Drainage After Lymph Node Dissection With Lobectomy.

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Norfolk

Sentara Norfolk General Hospital/Sentara Heart Hospital, Norfolk, Virginia, United States, 23507

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients undergoing resection for stage 1, 2 or 3A lung cancer.
  • * Patients between the ages of 20-75.
  • * History of Congestive Heart Failure.
  • * History of renal failure, ie., creatinine greater than 2.2.
  • * Patients with bulky or matted lymph nodes in stage 3A.
  • * Current pregnancy.
  • * Current participation in another study involving an investigational device or drug.

Ages Eligible for Study

20 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sentara Cardiovascular Research Institute,

Joseph Newton, MD, PRINCIPAL_INVESTIGATOR, Sentara Cardiovascular Research Institute

Study Record Dates

2024-11